Open3.210 | Close3.265 |
Vol / Avg.1.422K / 22.978K | Mkt Cap161.964M |
Day Range3.130 - 3.265 | 52 Wk Range2.894 - 4.750 |
Genfit Stock (NASDAQ: GNFT) stock price, news, charts, stock research, profile.
Open3.210 | Close3.265 |
Vol / Avg.1.422K / 22.978K | Mkt Cap161.964M |
Day Range3.130 - 3.265 | 52 Wk Range2.894 - 4.750 |
H1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.450 | ||||||
REV | 16.628M |
FY 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.490 | ||||||
REV | 27.116M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-21 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 11.00 |
2023-07-03 | HC Wainwright & Co. | Ed Arce | Maintains | BuyBuy | Raises | 9.00 | 11.00 |
2023-06-01 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 9.00 |
2023-05-24 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 9.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
GNFT | Genfit | 1.56% | 162M |
MOLN | Molecular Partners | 4.05% | 143.5M |
LRMR | Larimar Therapeutics | -3.79% | 144.9M |
ALT | Altimmune | 16.77% | 198.3M |
ARQT | Arcutis Biotherapeutics | 8.15% | 187.8M |
You can purchase shares of Genfit (NASDAQ: GNFT) through any online brokerage.
Other companies in Genfit’s space includes: Molecular Partners (NASDAQ:MOLN), Larimar Therapeutics (NASDAQ:LRMR), Altimmune (NASDAQ:ALT), Arcutis Biotherapeutics (NASDAQ:ARQT) and Monte Rosa Therapeutics (NASDAQ:GLUE).
The latest price target for Genfit (NASDAQ: GNFT) was reported by HC Wainwright & Co. on Thursday, September 21, 2023. The analyst firm set a price target for 11.00 expecting GNFT to rise to within 12 months (a possible 238.46% upside). 5 analyst firms have reported ratings in the last year.
The stock price for Genfit (NASDAQ: GNFT) is $3.25 last updated November 29, 2023 at 1:58 PM UTC.
There is no dividend information for Genfit.
Genfit’s H1 earnings are confirmed for Wednesday, September 20, 2023.
There is no upcoming split for Genfit.
Genfit is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.